Yes, STARD1 (Steroidogenic Acute Regulatory Protein D1) plays a key role in promoting cholestatic liver injury and disease progression. Cholestatic liver diseases occur when bile acids, which are made from cholesterol, build up in the liver cells (hepatocytes).
Yes, STARD1 (Steroidogenic Acute Regulatory Protein D1) plays a key role in promoting cholestatic liver injury and disease progression. Cholestatic liver diseases occur when bile acids, which are made from cholesterol, build up in the liver cells (hepatocytes). This buildup causes liver damage, inflammation, scarring (fibrosis), and can eventually lead to cirrhosis.
STARD1 is a protein that helps transport cholesterol into mitochondria, where it can be used to make bile acids through a specific pathway. However, too much mitochondrial cholesterol, facilitated by STARD1, disrupts the liver’s natural defenses against oxidative stress. This makes the liver more vulnerable to damage from toxic bile acids.
Studies in mice have shown that removing STARD1 specifically from liver cells (Stard1^Δhep^ mice) protects them from cholestatic injury. These mice had lower levels of harmful bile acids and mitochondrial cholesterol, less oxidative stress, and better antioxidant defenses, particularly higher levels of mitochondrial glutathione (mGSH). As a result, they experienced less liver inflammation and fibrosis compared to normal mice.
In humans, patients with primary biliary cholangitis (PBC), a type of cholestatic liver disease, show higher levels of STARD1 in their liver, linking it to disease severity. Targeting STARD1 or its effects on mitochondrial cholesterol and glutathione metabolism could be a promising treatment strategy for cholestatic liver diseases.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.